- HIV AIDS Myths and Facts Slideshow Pictures
- Take the HIV/AIDS Quiz
- AIDS Retrospective Slideshow Pictures
Does Viracept (nelfinavir) cause side effects?
During infection with HIV, the HIV virus multiplies within the body's cells. Viruses are released from the cells and spread throughout the body where they infect other cells. In this manner, HIV infection is perpetuated among new cells that the body continually produces.
During the production of the viruses, new proteins are made. Some of the proteins are structural proteins that form the body of the virus. Other proteins are enzymes which manufacture DNA and other components for the new viruses.
Protease is the enzyme that forms the new structural proteins and enzymes. Viracept blocks the activity of protease and results in the formation of defective viruses that are unable to infect the body's cells.
As a result, the number of viruses in the body (the viral load) decreases. Viracept does not prevent the transmission of HIV among individuals, and it does not cure HIV infections or AIDS.
Common side effects of Viracept include
- gas (flatulence),
- allergic reactions,
- rash, and
- redistribution or accumulation of body fat.
Serious side effects of Viracept include
- yellowing skin and eyes (jaundice),
- metabolic disturbance,
- liver failure,
- failure of the pancreas (pancreatitis),
- increased cholesterol,
- worsening of diabetes,
- immune reconstitution syndrome (an inflammatory response to infection), and
- spontaneous bleeding in patients with hemophilia.
Drug interactions of Viracept include
- St. John's wort,
- calcium channel blockers,
- cholesterol-lowering medicines,
- drugs that weaken the immune system,
- insulin or oral diabetes medications,
- medicines to treat erectile dysfunction, and
- seizure medications.
Viracept is not expected to be harmful to an unborn baby, but HIV can be passed to a baby if the mother is not properly treated during pregnancy. Tell your doctor if you are pregnant or plan to become pregnant.
It is unknown if Viracept is secreted in breast milk. Nevertheless, HIV-infected mothers should not breastfeed because of the potential risk of transmitting HIV to an infant that is not infected.
What are the important side effects of Viracept (nelfinavir)?
The most common side effects are
Other important side effects Nelfinavir include:
- metabolic disturbance,
- liver failure and
- failure of the pancreas (pancreatitis).
Nelfinavir oral powder contains phenylalanine and should be avoided by individuals with phenylketonuria. Like other protease inhibitors, use of nelfinavir may be associated with redistribution or accumulation of body fat, increased cholesterol and worsening of diabetes.
Immune reconstitution syndrome, an inflammatory response to infection, may occur in patients treated with combinations of drugs for the treatment of HIV infection. There have been reports of spontaneous bleeding in patients with hemophilia treated with protease inhibitors.
Viracept (nelfinavir) side effects list for healthcare professionals
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Clinical Trials Experience: Adults And Adolescents (13 Years and Older)
The safety of Viracept was studied in over 5000 patients who received drug either alone or in combination with nucleoside analogues. The majority of adverse events were of mild intensity. The most frequently reported adverse event among patients receiving Viracept was diarrhea, which was generally of mild to moderate intensity.
Drug-related clinical adverse experiences of moderate or severe intensity in ≥ 2% of patients treated with Viracept coadministered with d4T and 3TC (Study 542) for up to 48 weeks, or with ZDV plus 3TC (Study 511) for up to 24 weeks are presented in Table 4.
Table 4: Percentage of Patients with Treatment-Emergent* Adverse Events of Moderate or Severe Intensity Reported in ≥ 2% of Adult and Adolescent Patients
|Adverse Events||Study 511 24 weeks||Study 542 48 weeks|
|Placebo + ZDV/3TC|
|500 mg TID Viracept + ZDV/3TC|
|750 mg TID Viracept + ZDV/3TC|
|1250 mg BID Viracept + d4T/3TC|
|750 mg TID Viracept + d4T/3TC|
|* Includes those adverse events at least possibly, probably or definitely related to study drug or of unknown relationship and excludes concurrent HIV conditions|
Adverse events occurring in less than 2% of patients receiving Viracept in all phase 2 and 3 clinical trials and considered at least possibly related or of unknown relationship to treatment and of at least moderate severity are listed below.
Metabolic/Nutritional System: increases in alkaline phosphatase, amylase, creatine phosphokinase, lactic dehydrogenase, SGOT, SGPT, and gamma-glutamyl transpeptidase; hyperlipemia, hyperuricemia, hyperglycemia, hypoglycemia, dehydration, and liver function tests abnormal.
Special Senses: acute iritis and eye disorder.
Urogenital System: kidney calculus, sexual dysfunction, and urine abnormality.
The percentage of patients with marked laboratory abnormalities in Studies 542 and 511 are presented in Table 5. Marked laboratory abnormalities are defined as a Grade 3 or 4 abnormality in a patient with a normal baseline value, or a Grade 4 abnormality in a patient with a Grade 1 abnormality at baseline.
Table 5: Percentage of Patients by Treatment Group with Marked Laboratory Abnormalities* in > 2% of Patients
|Study 511||Study 542|
|500 mg TID Viracept +ZDV/3TC|
|750 mg TID Viracept +ZDV/3TC|
|1250 mg BID Viracept+ d4T/3TC|
|750 mg TID Viracept+ d4T/3TC|
|* Marked laboratory abnormalities are defined as a shift from Grade 0 at baseline to at least Grade 3 or from Grade 1 to Grade 4|
Clinical Trials Experience: Pediatrics (2 to Less than 13 Years of Age)
Viracept has been studied in approximately 400 pediatric patients in clinical trials from birth to 13 years of age. The adverse event profile seen during pediatric clinical trials was similar to that for adults.
The most commonly reported drug-related, treatment-emergent adverse events reported in the pediatric studies included:
Diarrhea, regardless of assigned relationship to study drug, was reported in 39% to 47% of pediatric patients receiving Viracept in 2 of the larger treatment trials. Leukopenia/neutropenia was the laboratory abnormality most commonly reported as a significant event across the pediatric studies.
The following adverse reactions have been identified during post-approval use of Viracept. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Cardiovascular System: QTc prolongation, torsades de pointes.
Digestive System: jaundice.
Metabolic/Nutritional System: bilirubinemia, metabolic acidosis.
What drugs interact with Viracept (nelfinavir)?
Potential For Viracept To Affect Other Drugs
Nelfinavir is an inhibitor of CYP3A. Coadministration of Viracept and drugs primarily metabolized by CYP3A (e.g., dihydropyridine calcium channel blockers, HMG-CoA reductase inhibitors, immunosuppressants, and PDE5 inhibitors) may result in increased plasma concentrations of such drugs that could increase or prolong both its therapeutic and adverse effects (see Tables 3 and 6).
Potential For Other Drugs To Affect Viracept
Nelfinavir is metabolized by CYP3A and CYP2C19. Coadministration of Viracept and drugs that induce CYP3A or CYP2C19, such as rifampin, may decrease nelfinavir plasma concentrations and reduce its therapeutic effect. Coadministration of Viracept and drugs that inhibit CYP3A or CYP2C19 may increase nelfinavir plasma concentrations.
Established And Other Potentially Significant Drug Interactions
Table 6 provides the effect on concentrations of Viracept or concomitant drug as a result of coadministration with Viracept. These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious adverse events or loss of efficacy.
Table 6: Established and Other Potentially Significant
Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug
Interaction Studies [see (Tables 12 and 13) for magnitude
|Concomitant Drug Class: Drug Name||Effect on Concentration||Clinical Comment|
|HIV Antiviral Agents: Reverse Transcriptase Inhibitors|
|Delavirdine||↑ nelfinavir (Cmin)
|Concentrations of nelfinavir were increased while concentrations of delavirdine were decreased when the two agents were coadministered. Appropriate doses of the combination, with respect to safety and efficacy, have not been established.|
|Nevirapine||↓ nelfinavir (Cmin)||Concentrations of nelfinavir were decreased when coadministered with nevirapine. An appropriate dose of nelfinavir with respect to safety and efficacy has not been established.|
|Didanosine||↔ nelfinavir||There was no change in nelfinavir concentration when coadministered with didanosine. However, it is recommended that didanosine be administered on an empty stomach; therefore, didanosine should be given one hour before or two hours after Viracept (given with food).|
|HIV Antiviral Agents: Protease Inhibitors|
|Concentrations of both indinavir and nelfinavir were increased when the two agents were coadministered. Appropriate doses for these combinations, with respect to safety and efficacy, have not been established.|
|Concentrations of nelfinavir were increased when coadministered with ritonavir. An appropriate dose of nelfinavir for this combination, with respect to safety and efficacy, has not been established.|
|Concentrations of both saquinavir and nelfinavir were increased when the two agents were coadministered. Appropriate doses for these combinations, with respect to safety and efficacy, have not been established.|
|Warfarin||Warfarin||Coadministration of warfarin and Viracept may affect concentrations of warfarin. It is recommended that the INR (international normalized ratio) be monitored carefully during treatment with Viracept, especially when commencing therapy.|
|Concentrations of nelfinavir may be decreased. Viracept may not be effective due to decreased nelfinavir plasma concentrations in patients taking these agents concomitantly. Phenytoin plasma/serum concentrations should be monitored; phenytoin dose may require adjustment to compensate for altered phenytoin concentration.|
|Trazodone||↑ trazodone||Concomitant use of trazodone and Viracept may increase plasma concentrations of trazodone. Adverse events of nausea, dizziness, hypotension and syncope have been observed following coadministration of trazodone and ritonavir. If trazodone is used with a CYP3A4 inhibitor such as Viracept, the combination should be used with caution and a lower dose of trazodone should be considered.|
|Colchicine||↑ colchicines||Patients with renal or hepatic impairment should not be given colchicine with Viracept due to the risk of colchicine toxicity.
Treatment of gout flares - co- administration of colchicine in patients on Viracept:
0.6 mg (1 tablet) x 1 dose, followed by 0.3 mg (half tablet) 1 hour later. Dose to be repeated no earlier than 3 days.
Prophylaxis of gout-flares - coadministration of colchicine in patients on Viracept:
If the original colchicine regimen was 0.6 mg twice a day, the regimen should be adjusted to 0.3 mg once a day. If the original colchicine regimen was 0.6 mg once a day, the regimen should be adjusted to 0.3 mg once every other day.
Treatment of familial Mediterranean fever (FMF)-coadministration of colchicine in patients on Viracept:
Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day).
(750 mg TID)
(1250 mg BID)
|It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with Viracept; 1250 mg BID is the preferred dose of Viracept when coadministered with rifabutin.|
|ENDOTHELIN RECEPTOR ANTAGONIST|
|Bosentan||↑ bosentan||Concentrations of bosentan may be increased when coadministered with Viracept. Coadministration of bosentan in patients on Viracept or coadministration of Viracept in patients on bosentan: Start at or adjust bosentan to 62.5 mg once daily or every other day based upon individual tolerability.|
|HMG-CoA REDUCTASE INHIBITORS|
|Titrate atorvastatin dose carefully and use the lowest necessary dose; do not exceed atorvastatin 40 mg/day.|
|Concentrations of these immunosuppressants and nelfinavir may be increased by coadministration of these agents with nelfinavir.|
|INHALED BETA AGONIST|
|Concurrent administration of salmeterol with Viracept is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia.|
|Fluticasone||↑ salmeterol||Concomitant use of fluticasone propionate and Viracept may increase plasma concentrations of fluticasone propionate. Use with caution. Consider alternatives to fluticasone propionate, particularly for long-term use.|
|Azithromycin||↑ azithromycin||Dose adjustment of azithromycin is not recommended, but close monitoring for known side effects such as liver enzyme abnormalities and hearing impairment is warranted.|
|Methadone||↓ methadone||Concentrations of methadone were decreased when coadministered with Viracept. Dosage of methadone may need to be increased when coadministered with Viracept.|
|Ethinyl estradiol Norethindrone||↓ ethinyl estradiol
|Concentrations of ethinyl estradiol and norethindrone were decreased when coadministered with Viracept. Alternative or additional contraceptive measures should be used when oral contraceptives containing ethinyl estradiol or norethindrone and Viracept are coadministered.|
|↑ PDE5 Inhibitors||Concomitant use of PDE5 inhibitors and Viracept should be undertaken with caution.
May result in an increase in PDE5 inhibitor-associated adverse events, including hypotension, syncope, visual disturbances, and priapism.
Use of PDE5 inhibitors for pulmonary arterial hypertension(PAH):
Start at or adjust ADCIRCA to 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability.
Use of PDE5 inhibitors for erectile dysfunction:
Sildenafil at a single dose not exceeding 25 mg in 48 hours, vardenafil at a single dose not exceeding 2.5 mg in 24 hours, or tadalafil at a single dose not exceeding 10 mg dose in 72 hours, is recommended. Use with increased monitoring for adverse events.
|PROTON PUMP INHIBITORS|
|Omeprazole||↓ nelfinavir||Omeprazole decreases the plasma concentrations of nelfinavir. Concomitant use of proton pump inhibitors and Viracept may lead to a loss of virologic response and development of resistance.|
|Quetiapine||↑ quetiapine||Initiation of Viracept in patients taking quetiapine: Consider alternative antiretroviral therapy to avoid increases in quetiapine drug exposures. If coadministration is necessary, reduce the quetiapine dose to 1/6 of the current dose and monitor for quetiapine-associated adverse reactions. Refer to the quetiapine prescribing information for recommendations on adverse reaction monitoring.
Initiation of quetiapine in patients taking Viracept:
Refer to the quetiapine prescribing information for initial dosing and titration of quetiapine.
Viracept (nelfinavir) is a protease inhibitor used to treat infections with the human immunodeficiency virus (HIV). Common side effects of Viracept include nausea, diarrhea, gas (flatulence), allergic reactions, rash, and redistribution or accumulation of body fat. Viracept is not expected to be harmful to an unborn baby, but HIV can be passed to a baby if the mother is not properly treated during pregnancy. It is unknown if Viracept is secreted in breast milk.
Multimedia: Slideshows, Images & Quizzes
HIV AIDS Facts: Symptoms and Treatments
What is HIV AIDS (human immunodeficiency virus-acquired immunodeficiency syndrome)? Discover myths and facts about living with...
What Are HIV & AIDS? Symptoms, Treatment, and Prevention
HIV, or human immunodeficiency virus, causes acquired immunodeficiency syndrome, or AIDS. Learn about HIV positive, being HIV...
HIV & AIDS Quiz: HIV Testing & Symptoms
Now, more than ever, you should know about HIV/AIDS, especially its causes, symptoms treatments, and complications. Take the...
Picture of HIV Lipodystrophy
HIV lipodystrophy describes a constellation of changes in subcutaneous and visceral fat distribution in patients on...
Picture of HIV Lipodystrophy Treatment
HIV lipodystrophy describes a constellation of changes in subcutaneous and visceral fat distribution in patients on...
Related Disease Conditions
HIV Early Signs and Stages
Human immunodeficiency virus or HIV, destroys important cells that fight disease and infection, which weakens a person's immune system. Some people with HIV don’t have any signs or symptoms. Early signs and symptoms of HIV infection include mononucleosis-like or flu-like symptoms, which include body aches, fever, and headache. Signs and symptoms begin around seven or eight years after HIV infection, which include weight loss, loss of energy and appetite, and swollen lymph nodes. There are 3 stages of HIV.
HIV and AIDS
Second Source article from WebMD
Can HIV be Cured Naturally?
HIV stands for human immunodeficiency virus. If someone has HIV it means that they have been diagnosed with the HIV infection. AIDS (acquired immune deficiency syndrome); however, is the most advanced or final stage of the HIV infection. It is important to get tested for HIV in the early stages of infection to minimize the damage to the immune system. Successful treatment aims to reduce HIV load to a level that is harmless to the body.
HIV vs. AIDS
Human immunodeficiency virus causes HIV infection. Acquired immunodeficiency syndrome (AIDS) is a condition that results after HIV has extensively damaged a person's immune system. Risk factors for HIV and AIDS include use of contaminated needles or syringes, unprotected sex, STDs, receiving a blood transfusion prior to 1985 in the United States, having many sex partners, and transmission from a mother to her child.
HIV/AIDS Facts: What Is HIV?
HIV (human immunodeficiency virus) is the precursor infection to AIDS (acquired immunodeficiency syndrome). HIV is transmitted through blood and genital secretions; most people get it through sexual contact or sharing needles for illegal IV drug use. HIV can be controlled by a strict drug regimen, but left unchecked, it leads to AIDS. In AIDS, the immune system collapses and the body falls prey to secondary, opportunistic infections and cancers that typically kill the person.
HIV/AIDS Testing: Diagnosis and Monitoring
HIV/AIDS diagnosis and monitoring have come a long way from the days when a diagnosis was a death sentence. Crucial parts of the effective treatment regimens developed in the last 40 years are consistent monitoring of the viral load (the amount of virus in the blood), and the immune cell count, which function as biological markers of the disease’s progression. Doctors also must test for drug resistance.
HIV Medications List and Drug Charts
The ultimate goal of HIV treatment is getting the viral load down below detectable levels. As long as those viral load and antibody levels are below a proscribed range, people with HIV can stave off AIDS and other serious symptoms. Antiviral treatment options usually include combinations of two NRTIs, often referred to as "nucs," and a third drug, typically being a boosted protease inhibitor, a NNRTI, often called "non-nucs," and integrase strand transfer inhibitors.
HIV/AIDS Infection Transmission and Prevention
HIV (human immunodeficiency virus) is spread through contact with genital fluids or blood of an infected person. The spread of HIV can occur when these secretions come in contact with tissues such as those lining the vagina, anal area, mouth, eyes (the mucus membranes), or with a break in the skin, such as from a cut or puncture by a needle.
What Are the Side Effects of HIV Medications?
It’s important to know the potential side effects of all the drugs you take to control your HIV infection, as well as potential drug interactions. All of the NNRTIs (nonnucleoside analogue reverse transcriptase inhibitors), for example, are associated with important drug-drug interactions so they must be used with caution in patients on other medications. Learn more about the side effects of the drugs in standard treatment regimens.
When should you start HIV medication?
Nearly everyone who is infected with HIV (human immunodeficiency virus) should start antiviral medication therapy as soon as they are diagnosed. Older guidelines recommended delaying treatment to help reduce the potential for drug side effects and viral resistance to treatment. Current thinking theorizes that early treatment may preserve more of the body's immune function.
Treatment & Diagnosis
- HIV-AIDS FAQs
- HIV Treatment, Medications, and Prevention
- HIV Urine Test Approved
- HIV Treatment - To Interrupt or Not
- Unprotected Sex Between HIV-Infected Partners: What's the Harm?
- HIV Transmission and Progression to AIDS Continues
- Physical and Biochemical Changes in HIV Disease
- Babies On The Breast Of HIV Moms
- HIV / AIDS Conference Update 2005 - Index
- Can HIV Cause Kaposi's Sarcoma?
- Do You Need Antiretroviral Therapy for HIV with No Symptoms?
- Does HIV Cause Colorectal Cancer?
- Does Anti-Retroviral Therapy for HIV Cause Diabetes?
- How Long Should You Wait to Get an HIV Test?
- What Liver Problems Does HIV Cause?
- Does Circumcision Prevent HIV and AIDS?
- HIV Infection Facts, History, Causes, and Risk Factors
- HIV Tests, Symptoms, Signs, and Stages of Infection
- Baby "Cured" of HIV Infection
Medications & Supplements
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Professional side effects and drug interactions sections courtesy of the U.S. Food and Drug Administration.